Abliva AB (publ) (STO:ABLI)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.4440
+0.0010 (0.23%)
Inactive · Last trade price on Mar 17, 2025
196.79%
Market Cap 715.68M
Revenue (ttm) n/a
Net Income (ttm) -89.95M
Shares Out 1.61B
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 565,706
Average Volume 2,248,538
Open 0.4430
Previous Close 0.4430
Day's Range 0.4430 - 0.4500
52-Week Range 0.1140 - 0.4550
Beta 0.75
RSI 54.74
Earnings Date Feb 21, 2025

About Abliva AB

Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yung... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ABLI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.